A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.
"Treatment with low doses of decitabine in an animal model of breast cancer restored PRKD1 expression, reduced tumor size, and blocked metastasis to the lung," says the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic in Florida.
"The outcome of patients with invasive breast cancer is less than optimal despite many attempts to improve treatment, including advanced chemotherapy and hormonal therapy," says Dr. Storz. "We hope this study offers a new avenue to prevent breast cancer from becoming aggressive and untreatable."
The research team, which includes first author Sahra Borges, Ph.D., a postdoctoral researcher in Dr. Storz's lab, found that the gene coding for PRKD1 was silenced in all but one subtype of invasive breast cancer, including aggressive triple negative breast cancer. That subtype is invasive lobular carcinoma.
Dr. Borges also developed an assay that can be used to measure the amount of PRKD1 that is silenced in patients' breast tumors.
"Because we found that PRKD1 is increasingly silenced as breast cancer becomes aggressive and spreads, the hope is that this test can be further developed and used to predict which patients are at risk for cancer metastasis, and thus may benefit from decitabine," Dr. Borges says.
Decitabine, approved by the U.S. Food and Drug Administration for use in some blood cancers, is a demethylating agent, meaning that it can switch on beneficial genes such as PRKD1 that cancer has silenced in order to grow.
Treating genes that are silenced is much easier than trying to restore function of a mutated gene, Dr. Storz says. The normal function of PRKD1, which is expressed in cells of the mammary gland, is to maintain normal function by preventing cells from morphing into a state where they can dislodge and spread, he says.
The researchers hope this study will help them to design a clinical trial in collaboration with Mayo Clinic physicians using decitabine to promote re-expression of PRKD1 and agents that activate PRKD1.
Explore further: Scientists discover new drug targets for aggressive breast cancer
Medical Xpress on facebook
Related Stories
Drug duo turns on cancer-fighting gene in kidney, breast cancers
Jul 31, 2012
A potentially powerful new approach to treating two lethal metastatic cancers — triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer — has been discovered by researchers ...
Scientists discover new drug targets for aggressive breast cancer
Jul 26, 2013
Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported ...
Researchers decode origin of inflammation-driven pancreatic cancer
Aug 05, 2013
Researchers at Mayo Clinic in Florida have revealed the process by which chronic inflammation of the pancreas, pancreatitis, morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients ...
Researchers discover molecule that drives aggressive breast cancer
Jul 01, 2013
(Medical Xpress)—Recent studies by researchers at Thomas Jefferson University's Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. ...
New hope for hormone resistant breast cancer
Jul 22, 2013
A new finding provides fresh hope for the millions of women worldwide with oestrogen receptor positive breast cancer. Australian scientists have shown that a specific change, which occurs when tumours become resistant to ...
Recommended for you
The stress and cancer link: 'Master switch' stress gene enables cancer's spread
2 hours ago
In an unexpected finding, scientists have linked the activation of a stress gene in immune-system cells to the spread of breast cancer to other parts of the body.
Foreign-born hispanics have survival advantage in NSCLC
4 hours ago
(HealthDay)—Compared with non-Hispanic whites (NHWs) and U.S.-born Hispanics, foreign-born Hispanics with non-small-cell lung cancer (NSCLC) have a reduced risk of disease-specific mortality, according ...
Study helps explain increased melanoma risk in individuals with red hair
7 hours ago
A person's skin pigment, which determines hair color and skin tone, is influenced by the melanocortin-1 (MC1R) gene receptor. For the population's one to two percent of redheads, a mutation in MC1R accounts for their red ...
Targeted cancer treatment: Cause of skin infections identified
9 hours ago
Targeted, successful cancer treatments are very often accompanied by unpleasant side effects. Especially in anti-EGFR treatments the skin is often so badly affected by inflammations that patients consider ...
Scientists pinpoint a new molecular mechanism tied to pancreatic cancer
11 hours ago
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
New light-activated suncream will cut skin cancer
13 hours ago
With a Bank Holiday weekend around the corner and the expected return of sunny weather, families around Britain are hoping not to put the suncream away just yet.
User comments
© Medical Xpress 2011-2013, Phys.org network
A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.
"Treatment with low doses of decitabine in an animal model of breast cancer restored PRKD1 expression, reduced tumor size, and blocked metastasis to the lung," says the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic in Florida.
"The outcome of patients with invasive breast cancer is less than optimal despite many attempts to improve treatment, including advanced chemotherapy and hormonal therapy," says Dr. Storz. "We hope this study offers a new avenue to prevent breast cancer from becoming aggressive and untreatable."
The research team, which includes first author Sahra Borges, Ph.D., a postdoctoral researcher in Dr. Storz's lab, found that the gene coding for PRKD1 was silenced in all but one subtype of invasive breast cancer, including aggressive triple negative breast cancer. That subtype is invasive lobular carcinoma.
Dr. Borges also developed an assay that can be used to measure the amount of PRKD1 that is silenced in patients' breast tumors.
"Because we found that PRKD1 is increasingly silenced as breast cancer becomes aggressive and spreads, the hope is that this test can be further developed and used to predict which patients are at risk for cancer metastasis, and thus may benefit from decitabine," Dr. Borges says.
Decitabine, approved by the U.S. Food and Drug Administration for use in some blood cancers, is a demethylating agent, meaning that it can switch on beneficial genes such as PRKD1 that cancer has silenced in order to grow.
Treating genes that are silenced is much easier than trying to restore function of a mutated gene, Dr. Storz says. The normal function of PRKD1, which is expressed in cells of the mammary gland, is to maintain normal function by preventing cells from morphing into a state where they can dislodge and spread, he says.
The researchers hope this study will help them to design a clinical trial in collaboration with Mayo Clinic physicians using decitabine to promote re-expression of PRKD1 and agents that activate PRKD1.
Explore further: Scientists discover new drug targets for aggressive breast cancer
Medical Xpress on facebook
Related Stories
Drug duo turns on cancer-fighting gene in kidney, breast cancers
Jul 31, 2012
A potentially powerful new approach to treating two lethal metastatic cancers — triple negative breast cancer and clear cell renal cell carcinoma, the most common form of kidney cancer — has been discovered by researchers ...
Scientists discover new drug targets for aggressive breast cancer
Jul 26, 2013
Scientists at A*STAR's Genome Institute of Singapore (GIS) led in a study that has identified genes that are potential targets for therapeutic drugs against aggressive breast cancer. These findings were reported ...
Researchers decode origin of inflammation-driven pancreatic cancer
Aug 05, 2013
Researchers at Mayo Clinic in Florida have revealed the process by which chronic inflammation of the pancreas, pancreatitis, morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients ...
Researchers discover molecule that drives aggressive breast cancer
Jul 01, 2013
(Medical Xpress)—Recent studies by researchers at Thomas Jefferson University's Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. ...
New hope for hormone resistant breast cancer
Jul 22, 2013
A new finding provides fresh hope for the millions of women worldwide with oestrogen receptor positive breast cancer. Australian scientists have shown that a specific change, which occurs when tumours become resistant to ...
Recommended for you
The stress and cancer link: 'Master switch' stress gene enables cancer's spread
2 hours ago
In an unexpected finding, scientists have linked the activation of a stress gene in immune-system cells to the spread of breast cancer to other parts of the body.
Foreign-born hispanics have survival advantage in NSCLC
4 hours ago
(HealthDay)—Compared with non-Hispanic whites (NHWs) and U.S.-born Hispanics, foreign-born Hispanics with non-small-cell lung cancer (NSCLC) have a reduced risk of disease-specific mortality, according ...
Study helps explain increased melanoma risk in individuals with red hair
7 hours ago
A person's skin pigment, which determines hair color and skin tone, is influenced by the melanocortin-1 (MC1R) gene receptor. For the population's one to two percent of redheads, a mutation in MC1R accounts for their red ...
Targeted cancer treatment: Cause of skin infections identified
9 hours ago
Targeted, successful cancer treatments are very often accompanied by unpleasant side effects. Especially in anti-EGFR treatments the skin is often so badly affected by inflammations that patients consider ...
Scientists pinpoint a new molecular mechanism tied to pancreatic cancer
11 hours ago
(Medical Xpress)—New research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) and Baylor College of Medicine could aid efforts to diagnose and treat one of the most lethal and hard-to-treat ...
New light-activated suncream will cut skin cancer
13 hours ago
With a Bank Holiday weekend around the corner and the expected return of sunny weather, families around Britain are hoping not to put the suncream away just yet.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment